What's New/
Latest news
- All
- Advocacy
- Experiences
- Guest Blog
- Information
- Research
- Reviews
- All
- Advocacy
- Experiences
- Guest Blog
- Information
- Research
- Reviews
Research New Zealand health survey data – a decade to be released
Have you ever been told by a doctor you have migraines [sic]? This is what ...
Read More
Information Biofeedback: an underused migraine treatment
There’s a treatment for migraine that is safe, has no side effects and may work ...
Read More
Experiences I tried Aimovig for six months. Here’s my verdict
Calcitonin gene-related peptide or CGRP for short. That’s the target of most of the new ...
Read More
Information Anxiety and migraine
Do you have trouble relaxing? Are you unable to control or stop worrying? Feel nervous, ...
Read More
Information Emgality Frequently Asked Questions (FAQs)
In September 2022, the second calcitonin gene-related monoclonal (CGRP) monoclonal antibody medication called Emgality (galcanezumab) ...
Read More
Information The link between migraine and depression
For Mental Health Awareness Week, we want to highlight that people with migraine disease are ...
Read More
AdvocacyResearch Few people on a benefit for migraine in New Zealand
If you’ve ever wondered how many people in Aotearoa New Zealand are on a benefit ...
Read More
Information Medication-overuse headache
How do you balance taking acute migraine medications as soon as you feel a migraine ...
Read More
Information Gepants – more migraine drugs we’re missing out on
The new vogue of migraine medications are those that block calcitonin gene-related peptide (CGRP), a ...
Read More
AdvocacyResearch More migraine data needed in New Zealand
New Zealand has a migraine data issue. The issue is the lack of data on ...
Read More
Reviews Migraine podcasts
I’m a big fan of podcasts. Having a long list of podcast episodes to listen ...
Read More
Advocacy Dealing with bad or unsolicited advice about migraine
How many times has someone found out I have migraine and they immediately offer me ...
Read More
